Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credit: WHO
Amid the ongoing Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus diseases, a group that includes all Ebola and Marburg virus infections.
Ebola and Marburg diseases are severe, often fatal illnesses that have caused repeated outbreaks across Africa. Since the discovery of the Marburg virus in 1967, there have been 72 documented outbreaks of Ebola and Marburg diseases.
There are currently no licensed vaccines and treatments for Marburg virus disease, as well as Bundibugyo and Sudan virus diseases. Thus, the WHO emphasized that early supportive care remains one of the most effective ways to improve survival.
"The current Bundibugyo virus outbreak is a stark reminder of the need for diligent, holistic and person-focused medical care to save lives and preserve human dignity. We encourage governments and authorities to integrate these new recommendations into preparedness and outbreak response to ensure high-quality care for everyone," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.
Also read: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations
The WHO has previously published disease-specific guidance on Ebola care and therapeutics. However, the newly released guidelines are the first to provide a comprehensive framework covering all filovirus diseases, including Ebola and Marburg.
Developed through consultations with global experts and based on the latest scientific evidence, the guidelines contain 16 evidence-based recommendations focused on improving supportive care and reducing mortality.
The recommendations are designed to help frontline healthcare workers:
Key Recommendations include:
The WHO also recommended structured after-care programs for survivors to support recovery, improve long-term well-being, and reduce the risk of infections linked to viral persistence after recovery.
For Bundibugyo virus disease and other filovirus infections, WHO stressed that early recognition, rapid referral, and optimized supportive care remain the foundation of patient management.
Effective supportive care can reduce complications, improve survival, and provide the basis for evaluating potential antiviral treatments through future clinical research.
Meanwhile, the Africa Centers for Disease Control and Prevention (Africa CDC) has raised concerns about significant weaknesses in contact-tracing efforts during the ongoing outbreak.
According to Africa CDC Director-General Dr. Jean Kaseya, more than 28,000 people who have been in contact with confirmed Ebola patients are currently not being monitored.
Responders should be tracking approximately 33,080 contacts, but only 4,112 are being actively followed, he said during a high-level meeting.
The agency warned that the outbreak is spreading at a pace that surveillance systems are struggling to keep up with.
Read More: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study
As per latest update till June 15, there are 827 confirmed Ebola cases linked to the outbreak in the Congo and 196 confirmed death.
Health officials estimate that each infected person may have come into contact with around 40 other individuals, creating a large pool of people at risk of infection.
Because Ebola can take up to 21 days for symptoms to appear, all identified contacts should ideally be monitored throughout the incubation period.
Africa CDC officials cautioned that without stronger surveillance and contact-tracing efforts, controlling the outbreak will become increasingly difficult, despite advances in clinical care and patient management.
Credit: iStock
Yet another study has highlighted the cardiovascular benefits of COVID-19 vaccination, particularly among older adults and people with underlying health conditions.
A new study involving nearly one million people, published in the journal JAMA Internal Medicine, found that COVID vaccination reduced the risk of major cardiovascular events associated with the virus—including heart attacks, strokes, and hospitalizations due to heart disease—by about 40 per cent.
The protective effect was most pronounced among adults aged 75 years and older, as well as individuals with pre-existing conditions such as cardiovascular disease, diabetes, and chronic lung disease.
The findings add to a growing body of evidence suggesting that COVID vaccines offer benefits beyond preventing severe infection.
Researchers also found that vaccination modestly reduced the risk of cardiovascular events, hospitalizations, and deaths from all causes, including those not directly linked to COVID.
"Extrapolating these estimates to a population of one million people, vaccination could plausibly be associated with averting approximately 2,370 major cardiovascular events and 1,580 deaths over an eight-month period," the study noted.
"It tells us that these vaccines have actually brought beneficial effects even in people who don't really know that they have contracted COVID-19," said Dr. Ziyad Al-Aly, physician-scientist and senior clinical epidemiologist at Washington University in St. Louis and co-author of the study, the Washington Post reported.
Also read: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study
Several previous studies have shown that COVID vaccination lowers the risk of heart attacks and strokes. However, researchers wanted to determine whether those benefits continued in the years after the onset of the pandemic, especially as both the virus and vaccine formulations evolved.
"Vaccine formulations have changed, and also the virus itself has changed over time," Al-Aly said. "But we found that the more recent vaccine formulations still protected against heart conditions."
The study analyzed nearly one million veterans receiving care through the US Department of Veterans Affairs health system between 2024 and 2025.
The participants were divided into two groups: individuals who received only the seasonal influenza vaccine and those who received both the flu vaccine and the updated COVID-19 vaccine during the same season. The analysis included multiple vaccine types, including mRNA vaccines and the Novavax vaccine.
Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn
Participants were followed for approximately eight months. The results showed that people who received a COVID vaccine had a 37.7 per cent lower risk of developing COVID-associated cardiovascular complications.
Vaccinated individuals were also about 6 per cent less likely to experience severe cardiovascular events overall, including those not directly linked to COVID-19 infection.
In addition, vaccination was associated with:
While these percentages may appear modest, researchers emphasized that the public health impact is substantial.
According to Al-Aly, for every 10,000 people vaccinated, the findings translate into preventing approximately:
COVID-19 vaccines have previously been linked to rare cases of myocarditis and pericarditis, conditions involving inflammation of the heart muscle and its surrounding lining.
However, experts note that these cases are uncommon and generally mild. Public health authorities continue to maintain that the benefits of vaccination far outweigh the potential risks.
Credit: University of Utah
A popular kratom drink, often marketed as a natural alternative to pharmaceutical drugs, could become the next major addiction crisis in the United States, addiction specialists are warning.
The substance, sometimes dubbed "gas-station heroin," is already banned in at least eight US states—Alabama, Arkansas, Connecticut, Indiana, Louisiana, Tennessee, Vermont, and Wisconsin. Several other states, including Iowa and Idaho, are considering restrictions or outright bans.
Tennessee looks to make a statewide ban effective from July 1. Earlier this month, Idaho Falls approved a local ban on kratom sales that will also take effect on July 1, the media report said.
While some jurisdictions are targeting synthetic forms of kratom rather than the plant itself, concerns over addiction, overdose risks, and easy accessibility continue to grow.
Last year, US Health and Human Services Secretary Robert F. Kennedy Jr. criticized the widespread availability of kratom products, including 7-hydroxymitragynine (7-OH), a potent kratom-derived compound, sold at gas stations and marketed in child-friendly forms such as gummies.
"It is a sinister, sinister industry," Kennedy said.
Kratom is a plant-based substance derived from the Mitragyna speciosa tree, native to Southeast Asia. Traditionally used in countries such as Thailand and Malaysia for pain relief and increased energy, it has gained popularity in the US as an over-the-counter supplement.
Kratom products are sold in various forms, including powders, capsules, teas, drinks, and gummies.
At lower doses, kratom acts as a stimulant. At higher doses, it can produce sedative and opioid-like effects. While it remains legal in many parts of the US, the Food and Drug Administration (FDA) has classified kratom as a "drug of concern" and has not approved it for any medical use.
Also read: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study
Health experts point to a sharp increase in kratom-related hospitalizations as evidence of a growing problem.
According to a University of Virginia study, there were 43 hospitalizations linked solely to kratom in 2015. By 2025, that number had risen to 538.
Researchers noted that the surge coincided with the emergence of highly concentrated synthetic products, including 7-OH.
"It is increasing the prevalence of opioid use disorder," Dr. Andrew Kolodny, director of the Opioid Policy Research Collaborative at Brandeis University, was quoted as saying to The Guardian.
"Being able to buy an opioid at a convenience store is going to make the opioid crisis worse," he added.
Mac Haddow, the association's senior fellow for public policy, denied that kratom itself is inherently addictive or dangerous. He argued that the real issue is 7-OH, which is significantly more potent than traditional kratom powder.
7-hydroxymitragynine (7-OH) is a naturally occurring compound found in kratom, and it is far more potent. While kratom itself contains a mixture of alkaloids, 7-OH is an isolated extract or concentrated form that interacts with the body’s opioid receptors much more strongly.
Read More: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant
Dr. Angad Madan, Medical Director of St. Peter's Addiction Recovery Center (SPARC), said many users mistakenly believe kratom is simply a harmless herbal supplement.
"Many patients do not know that it's a substance of addiction or misuse. Many patients just think it's a herbal supplement. I think it's false advertising, and it's resulting in another opioid epidemic that New York doesn't really need," he was quoted as saying to WNYT.
Madan added that kratom-related dependence is becoming increasingly common in treatment settings.
"Kratom, also known as 7-OH or 7-hydroxymitragynine, is the number one new substance addiction that I've seen at SPARC across all levels of care," he said.
© 2024 Bennett, Coleman & Company Limited